Clinical Trial Update: Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated Zevalin (ibritumomab tiuxetan) for patients with incomplete response to chemotherapy prior to autologous stem cell transplantation in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Tufts Medical Center | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2016-10-28